Key Highlights
- LeonaBio (NASDAQ:LONA) reported a third-quarter net loss of USD 21.2 million, or USD 0.89 per share, compared with USD 6.6 million, or USD 1.68 per share, a year earlier.
- Research and development expense rose to USD 14.6 million from USD 2.8 million, with lasofoxifene program costs up USD 10.5 million.
- Cash, cash equivalents and investments were USD 32.3 million at September 30, 2026, which the company says will not cover 12 months of planned spending.
- The nine-month net loss was USD 73.1 million, including a USD 16.3 million non-cash charge from a change in Fair Value of a pre-funded warrant.
Lasofoxifene Spending Triples the Quarterly Loss
LeonaBio (NASDAQ:LONA) filed its Quarterly Report on November 16, 2026. The Bothell, Washington company, formerly Athira Pharma, is a clinical-stage biopharmaceutical Business focused on treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. It acquired rights in December 2025 to lasofoxifene for ESR1-mutated metastatic breast cancer and also holds brelgometon, a Phase 2 ready ALS program. The third-quarter net loss was USD 21.2 million against USD 6.6 million. Research and Development expense climbed USD 11.8 million to USD 14.6 million, and lasofoxifene program costs added USD 10.5 million of that rise.
Nine-Month Loss Includes a USD 16.3 Million Warrant Charge
General and administrative expense rose to USD 6.9 million from USD 4.0 million on higher personnel costs, including Stock Compensation of USD 2.7 million. Over nine months, research and development expense was USD 39.0 million against USD 10.8 million, with lasofoxifene costs of USD 28.3 million and a USD 1.2 million gain from a milestone Liability fair value change. General and administrative expense was USD 20.3 million. The net loss of USD 73.1 million, or USD 3.30 per share, also included a USD 16.3 million non-cash charge tied to a pre-funded warrant held by Sermonix. Fosgonimeton and brelgometon spending each fell about USD 2.0 million as resources moved toward the breast cancer program. Other income, net, rose to USD 1.3 million from USD 1.0 million on higher balances of securities, though the company expects interest income to shrink as cash is spent. Personnel-related research costs rose USD 3.3 million over the nine months.
Going Concern Doubt and a Narrower Path to Capital
Cash used in operations over nine months was USD 56.8 million, compared with USD 26.3 million a year earlier. Cash, cash equivalents and investments of USD 32.3 million are not expected to fund operations for at least 12 months, which raises substantial doubt about continuing as a going concern. The accumulated Deficit was USD 584.9 million, and the company has raised USD 489.8 million in net proceeds since inception, including about USD 90 million from a December 2025 private placement. Series A warrants from that Placement expired unexercised on October 19, 2026 and brought in no capital. The company is ineligible to use a Form S-3 registration statement through December 2026 after a late filing, and 13,076,348 common shares were outstanding on November 13, 2026.
Where Things Stand
The loss tripled because the company shifted from early research to funding a late-stage cancer program. LeonaBio (NASDAQ:LONA) spent USD 14.6 million on research in the quarter, driven by lasofoxifene, and cash of USD 32.3 million is below what the plan requires for the next year. With warrants expired unexercised and shelf registration unavailable through December 2026, funding Options are narrower. Investors will likely watch for any financing, Partnership or change to the operating plan alongside progress in the breast cancer program.






Please wait processing your request...